FIELD: immunology.
SUBSTANCE: use of the composition for the treatment of IL-33-associated disease in mammals has been proposed. The composition contains an effective amount of an antibody or antigen-binding fragment binding IL-33 and a pharmacologically acceptable carrier.
EFFECT: composition effectively neutralizes the activity of IL-33 and is suitable for the treatment of inflammatory disease, autoimmune disease and cancer.
13 cl, 7 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF APPLICATION | 2016 |
|
RU2827926C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
